| Display title | Chemistry:Saridegib |
| Default sort key | Saridegib |
| Page length (in bytes) | 4,370 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 816092 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>MainAI5 |
| Date of page creation | 01:33, 13 August 2021 |
| Latest editor | imported>MainAI5 |
| Date of latest edit | 01:33, 13 August 2021 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Saridegib, also known as IPI-926, is an experimental drug candidate undergoing clinical trials for the treatment of various types of cancer, including hard-to-treat hematologic malignancies such as myelofibrosis and ligand-dependent tumors such as chondrosarcoma. IPI-926 exhibits its pharmacological... |
